News just in: Compulsory License application for Dasatinib rejected by Indian Patent Office

Indian Patent Office rejected the Compulsory License application filed by the Indian generic company- BDR Pharmaceuticals (filed in March 2013) for cancer drug Dasatinib used for the treatment of chronic myeloid leukemia. The application was rejected on procedural grounds.

The rejection order can be viewed here.

This entry was posted in Compulsory Licensing, Indian Patent Law, Patent Injunction. Bookmark the permalink.

One Response to News just in: Compulsory License application for Dasatinib rejected by Indian Patent Office

  1. ahmed says:

    see the poor patients not the MNC’S…………

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s